Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome

Table 1

Patient and tumor characteristics for all patients and patients in oncological follow-up.

	All patients (surgical follow-up) ( = 17)	Oncological follow-up ( = 13)
Median age, years (range)	65 (48–77)	65 (48–77)
Median body mass index, kg/m^2 (range)	28,9 (23,3–32,7)	24,7 (23,3–32,7)
Median PSA at diagnosis, ng/mL (range)	12 (5,2–38)	12 (5,9–38)
Gleason score, (%)
6	1 (6)	1 (8)
7 (3 + 4)	5 (29)	4 (31)
7 (4 + 3)	3 (18)	2 (15)
8	5 (29)	4 (31)
9	3 (18)	2 (15)
10	—	—
Clinical tumor stage, (%)
T2	6 (35)	5 (38)
T3a	4 (24)	4 (31)
T3b	3 (18)	1 (8)
T4	1 (6)	1 (8)
Unknown	3 (18)	2 (15)
Primary treatment, (%)
Surgery	14 (82)	11 (85)
Radiotherapy	2 (12)	2 (15)
High-intensity, focused ultrasound	1 (6)	—
Previous PLND, (%)	5 (29)	—
Median PSA at SLND, ng/mL (range)	2,01 (0,24–26,54)	2,01 (0,69–26,54)
Median PSAdt at SLND, months (range)	5,3 (1,5–46,5)	5,1 (1,6–19,8)
Median follow up, months (range)	22 (4–60)	21 (4–60)

PSA = prostate specific antigen; PSAdt = PSA doubling time; PLND = pelvic lymph node dissection; SLND = salvage pelvic lymph node dissection.